34 results
8-K
EX-10.2
ARAV
Aravive Inc
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
Rights. At all times during and after Service Provider’s engagement, Service Provider will hold in confidence and will not disclose, use, lecture upon … Provider’s engagement, Service Provider will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company
8-K
4docho kbe9p
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
l78icq
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.2
on3ueawfvwldw1ri2
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.2
uu43sn yst6h45honm
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
ha8lepxuhim 7nk
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
h4ppv z8v6ezabd
13 Jan 20
Other Events
8:06am
8-K
EX-10.4
ijrudvra9 sp
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
umhhc5wafmazh
2 Dec 19
Other Events
5:18pm
424B5
a325zopa
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
lt4 fstgw2y
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
1jyscahxv6hd0 9t
20 Nov 19
Other Events
7:05am